Dapagliflozin in Non Alcoholic Fatty Liver Disease Associated Cirrhosis and Its Role in Preventing Development of Chronic Kidney Disease.
Condition(s):NAFLD CirrhosisLast Updated:May 8, 2023Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):NAFLD CirrhosisLast Updated:May 8, 2023Not yet recruiting
Condition(s):Non-Alcoholic SteatohepatitisLast Updated:September 16, 2021Completed
Condition(s):Non-Alcoholic Fatty Liver Disease; Non Insulin Dependent Diabetes; ALTLast Updated:March 17, 2020Unknown status
Condition(s):Nonalcoholic Fatty Liver DiseaseLast Updated:March 25, 2022Completed
Condition(s):Nonalcoholic Steatohepatitis; Nonalcoholic Fatty Liver Disease; Type 2 Diabetes MellitusLast Updated:April 5, 2017Completed
Condition(s):Nonalcoholic Steatohepatitis (NASH) With FibrosisLast Updated:March 23, 2022Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.